As of January 22, 2025, Leap Therapeutics (LPTX) has a market cap of $88.131 million USD. According to our data, Leap Therapeutics is ranked No.7782 in global market value.
Year | Market Cap | %Change |
---|---|---|
Jan 22, 2025 | $88.13 M |
-20.00%
|
Dec 31, 2024 | $0.11 B |
-30.64%
|
Dec 29, 2023 | $0.16 B |
-7.89%
|
Dec 30, 2022 | $0.17 B |
-86.11%
|
Dec 31, 2021 | $1.24 B |
44.00%
|
Dec 31, 2020 | $0.86 B |
100.89%
|
Dec 31, 2019 | $0.43 B |
-44.00%
|
Dec 31, 2018 | $0.77 B |
-67.95%
|
Dec 29, 2017 | $2.39 B |
100%
|
Name | Market Cap | Market cap difference | Regions |
---|---|---|---|
MacroGenics
MGNX
|
$0.19 B |
-0.000 M
|
USA
|
Zymeworks
ZYME
|
$1.01 B |
-0.000 M
|
Canada
|
Iovance Biotherapeutics
IOVA
|
$1.83 B |
-0.000 M
|
USA
|
Fate Therapeutics
FATE
|
$0.15 B |
0.000 M
|
USA
|
Adaptimmune Therapeutics
ADAP
|
$0.15 B |
0.000 M
|
UK
|
Arcus Biosciences
RCUS
|
$1.23 B |
-0.000 M
|
USA
|
Nektar Therapeutics
NKTR
|
$0.17 B |
0.000 M
|
USA
|
Exelixis
EXEL
|
$9.39 B |
0.000 M
|
USA
|
Blueprint Medicines
BPMC
|
$7.06 B |
-0.000 M
|
USA
|
Deciphera Pharmaceuticals
DCPH
|
$2.21 B |
2.213 B
|
USA
|
Market Cap | = | LPTX Stock Price | * | LPTX Shares Outstanding |
= | $2.30 | * | 38.32 M | |
= | $88.13 M |